The 2,100 shares were acquired for ~$100,000 on August 5, 2026. This transaction represents a 14% in

Michael F. Mahoney deployed ~$10.0 million on August 3, 2026, to acquire ~200,000 shares at a weight

MARLBOROUGH, Mass., Aug. 10, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will par

Boston Scientific's 2026 guidance cut tests its recovery as WATCHMAN weakness, EP share losses and d

Boston Scientific's cheaper valuation offers upside, but weaker guidance, share losses, higher debt

Boston Scientific ( BSX ) manufactures medical devices and products used in various interventional m

First National Bank of Mount Dora Trust Investment Services purchased a new stake in Boston Scientif

After a week of wild swings that rattled portfolios and left investors guessing, Wall Street analyst

Bank of America Corp DE trimmed its position in Boston Scientific Corporation (NYSE: BSX) by 9.4% in

UBS analyst Patrick Wood maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price t

ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading throm

Citigroup analyst Joanne Wuensch maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the

RBC Capital analyst Kendall Au maintains Boston Scientific (NYSE:BSX) with a Outperform and lower

TD Cowen analyst Joshua Jennings maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the

Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:BSX) with a Buy and

Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:BSX) with a Buy and

BSX faces WATCHMAN and EP pressures as management cuts outlook while highlighting cost savings and n

Evercore ISI Group analyst Vijay Kumar maintains Boston Scientific (NYSE:BSX) with a Outperform a

Boston Scientific retains my buy rating with a $66 price target, reflecting 44% upside if negative e

Wells Fargo analyst Larry Biegelsen maintains Boston Scientific (NYSE:BSX) with a Equal-Weight an

Boston Scientific NYSE: BSX reported second-quarter 2026 revenue growth at the high end of its guida

BTIG analyst Marie Thibault maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the pric

Organic Sales Growth: 7% in Q2 2026, driven by Interventional Cardiology, Endoscopy, and Neuromodula

Boston Scientific Corp (NYSE:BSX, XETRA:BSX) reported second quarter results that exceeded analyst e

Boston Scientific Corporation (BSX) Q2 2026 Earnings Call Transcript

Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed

Boston Scientific Corporation (NYSE:BSX) stock is trading lower after the company cut its fiscal 202

Boston Scientific beat second-quarter estimates but lowered its 2026 sales and earnings outlook as r

BSX beats Q2 earnings and revenue estimates as cardiovascular growth, strong APAC and LACA sales, an

Boston Scientific (NYSE:BSX) is looking for Q3 Adj EPS of $0.80-$0.82 vs $0.83 analyst estimate. see

Boston Scientific (NYSE:BSX) lowers FY2026 Adj EPS guidance from $3.34-$3.41 to $3.28-$3.32 vs $3.36

Boston Scientific (NYSE:BSX) reported quarterly earnings of $0.86 per share which beat the analyst c

Boston Scientific (NYSE:BSX) has outperformed the market over the past 15 years by 1.23% on an annua

Oppenheimer analyst Suraj Kalia maintains Boston Scientific (NYSE:BSX) with a Outperform and lowe

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:BSX) with a Buy and

Mizuho analyst Anthony Petrone maintains Boston Scientific (NYSE:BSX) with a Outperform and lower

RBC Capital analyst Shagun Singh maintains Boston Scientific (NYSE:BSX) with a Outperform and low

July brings a sharp rotation trade in markets as investors shift from top performers to beaten-down

Needham analyst Mike Matson maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the pric

Evercore ISI Group analyst Vijay Kumar maintains Boston Scientific (NYSE:BSX) with a Outperform a

Stifel analyst Rick Wise maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price t

Jefferies analyst Matthew Taylor maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the

Boston Scientific (NYSE:BSX) has outperformed the market over the past 15 years by 1.07% on an annua

Jim Cramer recommends buying SOFI, and avoiding RIVN and BSX. He also says NIOBF is too speculative,

Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:BSX) with a Buy and

BTIG analyst Marie Thibault maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the pric

Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:BSX) with a Buy and

Weak guidance, analyst target cuts and declining energy prices weighed on Zscaler, AutoZone, PDD Hol

Wall Street analysts change outlook on top names. For all rating changes, see analyst ratings page.